When companies seek support with rare disease patient advocacy, ICON Biotech’s Bojana Mirosavljevic brings insights that are hard won. As a chemist, embryologist, and mother of a rare disease patient, she sees patient advocacy from the dual perspectives of science and caregiver. In this article we learn about her background and how it informs her work.
First hand advocacy experience
Mirosavljevic’s patient advocacy began when her daughter Zoya was three years and five months old. Up until that point Zoya was a healthy and happy little girl who met her developmental milestones. That changed when she began to have frequent epileptic seizures. For a while the seizures were stabilised with medication. When she began to lose her balance Mirosavljevic brought her for medical treatment. Unfortunately, her concerns were dismissed as being those of an over-anxious mother. Some time later Zoya lost all her motor functions within a day. She could no longer walk, talk or even recognise her parents. She also lost her swallow and had to be fed through a tube in her stomach. Her medical team were unable to identify the cause of these sudden, devastating changes to her health.
At this point Zoya’s doctor at Belgrade Children's Hospital suggested that the family bring her to a medical centre abroad. After carrying out her own research, Mirosavljevic brought Zoya to Great Ormond Street Hospital (GOSH), London to seek a diagnosis. The Mirosavljevics sought government-funding to travel but their application was refused. Like many rare disease families, they funded the medical and travel expenses themselves. They sold what they could, borrowed from friends and family and scraped together the €60,000 needed for Zoya’s medical transport and stay in GOSH. Almost immediately Zoya was diagnosed with Batten’s disease. This incurable fatal neurodegenerative genetic condition causes lipofuscin, a waste product, to accumulate in brain cells. Zoya died in 2013 at age nine.
Zoya’s legacy
In 2010 Mirosavljevic founded a rare disease patients association in Serbia, Zivot-Life, to support other rare disease families and advocate for change. She successfully sued the Serbian government for refusing to pay for Zoya’s travel for medical treatment. Within a week of Zoya’s death, with the support of her family and Zivot-Life, Mirosavljevic began a campaign to introduce Zoya’s Law to Serbian parliament. The objective was to accelerate the diagnosis of rare diseases and provide genetic testing and prenatal testing for rare disease families. After an emotionally exhausting fight, Zoya’s Law was unanimously passed by Serbian parliament in 2015.
The law has 4 main parts:
- If a patient cannot be diagnosed in Serbia within six months their doctor is required to send a blood or tissue sample to the global reference laboratory for further analysis
- Family members who are potential rare disease carriers can be tested to map the pathological gene within the family
- Families at risk of having children with a rare disease are enabled to have a prenatal diagnosis
- Preimplantation genetic testing (PGT) is offered to rare disease families who want to avail of it
Thanks to Zoya’s Law the average length of time to diagnose a rare disease in Serbia is 1.3 years. This is far quicker than the European average of 4.7 years.1 Zoya’s Law means that many Serbian families are spared the challenges that the Mirorsavljevic family endured. Zoya’s Law also enabled the Mirosavljevics to have two healthy girls using genetic tests and PGT. Mirosavljevic continues to advocate on behalf of rare disease patients in Serbia and has presented Zoya’s Law at the European Parliament in Brussels and the UN in New York in 2016.
Why patient advocacy strategy is essential for biotech
Many pharma and biotech companies aim to make their clinical trials more patient-centric. However, they do not always go about it in the best way. With her valuable insights and direct experience as a patient advocate, Mirosavljevic bridges the divide between patient advocacy organisations and biotech. Being patient-centric starts with including the patient voice. “There is no logic to doing something for the patient if you don’t speak with the patients,” Mirosavljevic says. She argues that integrating patients and patient advocacy organisations into trials from the beginning leads to better trial design and protocols. There is an urgent need for research into new treatments for rare diseases. More than 75% of patients with rare diseases are children, and 30% of patients die before reaching age five. After years spent seeking the correct diagnosis, and with few – if any – treatment options, “rare disease patients don’t have time to wait, trials are very often their only chance to try to survive.”
Much of Mirosavljevic’s working week is spent educating pharma and biotech companies on the value of connecting with patient advocacy organisations. This goes far beyond patient recruitment. Patient advocacy organisations are aware that they are much more than recruitment tools. Some regulatory authorities require that sponsors reach out to patient advocacy groups. Unfortunately, this has lead to some sponsors treating patient outreach as a box-ticking exercise. Instead, they should establish long term meaningful relationships with patient advocacy organisations. This is where Mirosavljevic excels. She works with biotechs to create strategies that include patients’ input to the clinical trial process. Rare disease patients and caregivers have insights on their diseases that the science community do not. They understand their diseases in a way that is impossible to outsiders. Their insights can be used to inform clinical outcomes and endpoints. Rare disease patient advocacy organisations are often highly networked, sharing information with other rare disease patients both in the same country and further afield. Patient advocacy organisations can also influence regulatory agencies, as Zoya’s Law demonstrates powerfully. This influence can enable more innovative clinical trial designs which push the boundaries of what is possible.
Collaboration and communication
Collaboration is high stakes for both sides and good communication is central to this. Language gaps can impact a patient's ability to find a diagnosis and join a clinical trial. Non-English speakers, both doctors and patients, may be unaware of the opportunities for trial participation when the information is only available in English. According to Tufts University Centre for the Study of Drug Development, 90% of nurses and physicians are comfortable discussing clinical trials with patients. Yet less than 0.2% refer patients to them.2 Patient advocacy organisations are more likely to be aware of clinical trials than many doctors, and more comfortable telling patients about them. Another challenge to rare disease patients is if there is no patient advocacy organisation for their specific disease in their home country. It can be difficult to connect with the right organisation abroad if you do not share a common language. This can lead to patients being isolated and excluded from clinical trial participation.
The future of patient advocacy and rare diseases
Mirosavljevic would like to see patient advocacy strategies adopted beyond rare disease research, for rare cancers and other more common diseases. Patients’ voices could be included more widely in healthcare and clinical trials. She’s excited by cell and gene therapy developments and the possibilities they offer the rare disease community. These new therapies raise both hope and many questions. For now the expense puts them beyond the reach for patients. However, in the future she believes they will be a gamechanger for rare disease treatment.
So many aspects of rare disease families’ lives are a struggle: to get the right diagnosis, fight for the necessary resources and find a potential treatment. Connecting with a patient advocacy organisation provides rare disease families and patients with much needed emotional and practical supports. Connecting biotechs with patient advocacy organisations provides the scientific knowledge and clinical trial opportunities that can lead to medical breakthroughs. Mirosavljevic began advocating for a single patient, Zoya. Since then she has transformed the lives of thousands of rare disease families in Serbia. Today at ICON Biotech her mission is to strengthen the connections between biotechs and patient advocacy organisations. In doing so she hopes to impact even more rare disease families worldwide by supporting the development of new therapies.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
-
Software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Behind Biotech: Stories of science and resilience
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel